Jean George
General Partner @ Advanced Technology Ventures
Boston, United States
Jean George is a Series B investor at Advanced Technology Ventures in Boston focused on Biotechnology and Biopharma. Jean is a General Partner of Lightstone Ventures. She focuses on biopharmaceutical and medical device investments out of the firm’s Boston office, where she also serves as a General Partner of Advanced Technology Ventures (ATV). Her representative investments include Acceleron Pharma (NASDAQ: XLRN), Calithera Biosciences (NASDAQ: CALA), CyteirTherapeutics, Disarm Therapeutics (acquired by Eli Lilly), Flex Pharma (NASDAQ: FLKS), Five Prime Therapeutics (NASDAQ: FPRX), Gemini Therapeutics, Hypnion (acquired by Eli Lilly), Locanabio Therapeutics, Portola Pharmaceuticals (NASDAQ: PTLA), Proteolix (acquired by Onyx Pharmaceuticals), Tizona Therapetics (acquired by Gilead), Verastem (NASDAQ: VSTM), and Zeltiq Aesthetics (NASDAQ: ZLTQ).
- Total investments:
- 15
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Jean George invests in
Stages Jean George invests in
Countries Jean George invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 9 (60%)
- Biopharma 5 (33%)
- Medical 4 (27%)
- Therapeutics 4 (27%)
- Pharmaceutical 4 (27%)
Stage
- Series B 5 (33%)
- Series C 3 (20%)
- Funding Round 2 (13%)
- Seed 1 (7%)
- Series A 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly ownedlead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks. | $80M / Series C / Feb 11, 2021 | ||
| Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly ownedlead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks. | $40.2M / Series B / Oct 15, 2019 | ||
| Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly ownedlead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks. | $29M / Series B / Mar 08, 2018 | ||
| Gemini Therapeutics is a precision medicine company focused on genetically defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical needs and our broad multimodal pipeline includes monoclonal antibodies,recombinant proteins, and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, they are developing a series of potentially first-in-class therapeutics. | $42.5M / Series A / Oct 17, 2017 | ||
| Gemini Therapeutics is a precision medicine company focused on genetically defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical needs and our broad multimodal pipeline includes monoclonal antibodies,recombinant proteins, and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, they are developing a series of potentially first-in-class therapeutics. | $2M / Seed / Apr 19, 2016 | ||
| The company is establishing collaborations with its scientific founders “to better understand whether regulatory T cells play a more prominent role in certain tumors,” he added. Although research suggests that Tregs cells play a more prominent role in creating immunosuppression in the microenvironment in some tumor types than others, “quitehonestly, the data are lacking. One of the ways we’re going to differentiate the company is to understand that relationship better. | $43M / Series B / Mar 08, 2016 | ||
| Astria Therapeutics is a biopharmaceutical company devoted to developing life-changing therapies for allergic and immunologic diseases. The company is advancing a pipeline of therapeutic candidates, including Navenibart for Hereditary Angioedema and STAR-0310 for Atopic Dermatitis. Astria Therapeutics conducts clinical trials and research, guidedby the patient community, to create new treatments. | $32.4M / Series B / Nov 14, 2013 | ||
| Calithera is a development stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer. They are applying Their scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival. | $35M / Series D / Oct 29, 2013 | ||
| Astria Therapeutics is a biopharmaceutical company devoted to developing life-changing therapies for allergic and immunologic diseases. The company is advancing a pipeline of therapeutic candidates, including Navenibart for Hereditary Angioedema and STAR-0310 for Atopic Dermatitis. Astria Therapeutics conducts clinical trials and research, guidedby the patient community, to create new treatments. | $9M / Feb 06, 2013 | ||
| Calithera is a development stage pharmaceutical company committed to discovering and developing novel small molecule therapeutics for the treatment of cancer. They are applying Their scientific expertise to build a pipeline of unique anti- cancer drugs that selectively target metabolic and apoptotic pathways critical to tumor growth and survival. | $2M / Series C / Dec 28, 2012 | ||
| See all 15 investments → | |||
Co-Investors
Advanced Technology Ventures (ATV) is a bi-coastal venture capital firm that focuses on communications, infrastructure, software and services, consumer technology, biopharmaceuticals, medical devices and cleantech.
Advanced Technology Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bill Wiberg
General Partner
|
|||
Bob Hower
General Partner
|
|||
|
Jean George
General Partner
|
|||
Mike Carusi
General Partner
|
|||
Richard Popp
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jean George invest in?
Jean George invests primarily in Biotechnology, Biopharma and Medical startups, most often at Series B and Series C stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jean George?
Public channels for Jean George include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jean George last invest?
The most recent investment recorded for Jean George closed in Feb 2021. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
